Explore

Trendline Trendline
Acadia Pharmaceuticals to Engage Investors at May 2026 Conferences

Acadia Pharmaceuticals to Engage Investors at May 2026 Conferences

Acadia Pharmaceuticals to Engage Investors at May 2026 Conferences
Trendline Trendline
Acadia Pharmaceuticals to Engage in May 2026 Investor Conferences

Acadia Pharmaceuticals to Engage in May 2026 Investor Conferences

Acadia Pharmaceuticals to Engage in May 2026 Investor Conferences
Trendline Trendline
NutriBand Reports $2.04M Revenue and $8.23M Net Loss for Fiscal Year 2026

NutriBand Reports $2.04M Revenue and $8.23M Net Loss for Fiscal Year 2026

NutriBand Reports $2.04M Revenue and $8.23M Net Loss for Fiscal Year 2026
Reuters Reuters
Eli Lilly raises annual forecasts as GLP-1 drugs fuel growth

Eli Lilly raises annual forecasts as GLP-1 drugs fuel growth

April 30 (Reuters) - Eli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for its weight-loss and diabetes drugs Zepbound and Mounjaro, in its first results since launching oral GLP-1 pill Foundayo.
Trendline Trendline
Alpha Cognition to Announce Q1 2026 Financial Results and Business Update

Alpha Cognition to Announce Q1 2026 Financial Results and Business Update

Alpha Cognition to Announce Q1 2026 Financial Results and Business Update
Trendline Trendline
Acadia Pharmaceuticals to Engage in Key Investor Conferences in May 2026

Acadia Pharmaceuticals to Engage in Key Investor Conferences in May 2026

Acadia Pharmaceuticals to Engage in Key Investor Conferences in May 2026
Trendline Trendline
Cellares and Cabaletta Bio Sign Long-Term Agreement for CAR T Cell Therapy Manufacturing

Cellares and Cabaletta Bio Sign Long-Term Agreement for CAR T Cell Therapy Manufacturing

Cellares and Cabaletta Bio Sign Long-Term Agreement for CAR T Cell Therapy Manufacturing
Trendline Trendline
GSK Awaits FDA Decision on Hepatitis B Drug Bepirovirsen with Potential for Major Health Impact

GSK Awaits FDA Decision on Hepatitis B Drug Bepirovirsen with Potential for Major Health Impact

GSK Awaits FDA Decision on Hepatitis B Drug Bepirovirsen with Potential for Major Health Impact
Trendline Trendline
Veradermics Initiates Public Offering to Expand Dermatology Innovations

Veradermics Initiates Public Offering to Expand Dermatology Innovations

Veradermics Initiates Public Offering to Expand Dermatology Innovations
Trendline Trendline
Veradermics Announces Conference Call to Discuss Phase 2/3 Study Results for Hair Loss Treatment

Veradermics Announces Conference Call to Discuss Phase 2/3 Study Results for Hair Loss Treatment

Veradermics Announces Conference Call to Discuss Phase 2/3 Study Results for Hair Loss Treatment
Trendline Trendline
Veradermics Announces Successful Late-Stage Trial for Hair Loss Drug VDPHL01

Veradermics Announces Successful Late-Stage Trial for Hair Loss Drug VDPHL01

Veradermics Announces Successful Late-Stage Trial for Hair Loss Drug VDPHL01
Trendline Trendline
Veradermics' Hair Loss Drug Shows Promising Results in Late-Stage Trial

Veradermics' Hair Loss Drug Shows Promising Results in Late-Stage Trial

Veradermics' Hair Loss Drug Shows Promising Results in Late-Stage Trial